Betaxolol Hydrochloride
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 317320

CAS#: 63659-19-8

Description: Betaxolol Hydrochloride is the hydrochloride salt form of betaxolol, a β1-AR selective adrenergic receptor antagonist. Betaxolol hydrochloride acts on the heart and circulatory system and decreases cardiac contractility and rate, and cardiac output levels. When applied topically in the eye, it lowers intraocular pressure by reducing aqueous humor secretion.


Chemical Structure

img
Betaxolol Hydrochloride
CAS# 63659-19-8

Theoretical Analysis

MedKoo Cat#: 317320
Name: Betaxolol Hydrochloride
CAS#: 63659-19-8
Chemical Formula: C18H30ClNO3
Exact Mass: 0.00
Molecular Weight: 343.890
Elemental Analysis: C, 62.87; H, 8.79; Cl, 10.31; N, 4.07; O, 13.96

Price and Availability

Size Price Availability Quantity
5mg USD 135 2 weeks
10mg USD 160 2 weeks
50mg USD 225 2 weeks
Bulk inquiry

Synonym: Betaxolol Hydrochloride; Betaxolol HCL; Betoptima; Kerlone; Betoptic; Kerlon; ALO 140102; ALO-1401-02; ALO140102

IUPAC/Chemical Name: Chemical Name: 1-[4-[2-(Cyclopropylmethoxy)ethyl]phenoxy]-3-isopropylamino-2-propanol hydrochloride

InChi Key: CHDPSNLJFOQTRK-UHFFFAOYSA-N

InChi Code: InChI=1S/C18H29NO3.ClH/c1-14(2)19-11-17(20)13-22-18-7-5-15(6-8-18)9-10-21-12-16-3-4-16;/h5-8,14,16-17,19-20H,3-4,9-13H2,1-2H3;1H

SMILES Code: CC(C)NCC(COC1=CC=C(C=C1)CCOCC2CC2)O.Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 343.89 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Al-Wadei MJ, Bakheit AH, Abdel-Aziz AA, Wani TA. Betaxolol: A comprehensive profile. Profiles Drug Subst Excip Relat Methodol. 2021;46:91-136. doi: 10.1016/bs.podrm.2020.07.002. Epub 2020 Aug 21. PMID: 33461701.


2: Hu J, Li H, Zhao Y, Ke Y, Rupenthal ID, Liu H, Ye J, Han X, Yang F, Li W, Lin H, Hou D. Critical Evaluation of Multifunctional Betaxolol Hydrochloride Nanoformulations for Effective Sustained Intraocular Pressure Reduction. Int J Nanomedicine. 2022 Dec 3;17:5915-5931. doi: 10.2147/IJN.S382968. PMID: 36506343; PMCID: PMC9729687.


3: Goldberg I. Betaxolol. Aust N Z J Ophthalmol. 1989 Feb;17(1):9-13. doi: 10.1111/j.1442-9071.1989.tb00483.x. PMID: 2569884.


4: Plager DA, Whitson JT, Netland PA, Vijaya L, Sathyan P, Sood D, Krishnadas SR, Robin AL, Gross RD, Scheib SA, Scott H, Dickerson JE; BETOPTIC S Pediatric Study Group. Betaxolol hydrochloride ophthalmic suspension 0.25% and timolol gel-forming solution 0.25% and 0.5% in pediatric glaucoma: a randomized clinical trial. J AAPOS. 2009 Aug;13(4):384-90. doi: 10.1016/j.jaapos.2009.04.017. PMID: 19683191.


5: Jain K, Kumar RS, Sood S, Dhyanandhan G. Betaxolol hydrochloride loaded chitosan nanoparticles for ocular delivery and their anti-glaucoma efficacy. Curr Drug Deliv. 2013 Oct;10(5):493-9. doi: 10.2174/1567201811310050001. PMID: 23410069.


6: Harrison R. Betaxolol and timolol. Arch Ophthalmol. 1984 Oct;102(10):1424, 1426. doi: 10.1001/archopht.1984.01040031154003. PMID: 6148923.


7: Takase B, Abe Y, Nagata M, Matsui T, Hattori H, Ohsuzu F, Ishihara M, Kurita A. Effect of betaxolol hydrochloride on heart rate variability indices during exercise stress testing in patients with hypertension. Biomed Pharmacother. 2005 Oct;59 Suppl 1:S158-62. doi: 10.1016/s0753-3322(05)80024-1. PMID: 16275486.


8: Auvity S, Chiadmi F, Cisternino S, Fontan JE, Schlatter J. A Rapid Stability- Indicating RP-HPLC Method for the Determination of Betaxolol Hydrochloride in Pharmaceutical Tablets. Anal Chem Insights. 2013;8:1-7. doi: 10.4137/ACI.S11256. Epub 2013 Mar 11. PMID: 23531643; PMCID: PMC3603494.


9: Burris JF, Riggs MC, Brinkley RR. Betaxolol and stuttering. Lancet. 1990 Jan 27;335(8683):223. doi: 10.1016/0140-6736(90)90311-r. PMID: 1967682.


10: Jain S. Betaxolol-associated anterior uveitis. Eye (Lond). 1994;8 ( Pt 6):708-9. doi: 10.1038/eye.1994.181. PMID: 7867841.


11: Huang W, Zhang N, Hua H, Liu T, Tang Y, Fu L, Yang Y, Ma X, Zhao Y. Preparation, pharmacokinetics and pharmacodynamics of ophthalmic thermosensitive in situ hydrogel of betaxolol hydrochloride. Biomed Pharmacother. 2016 Oct;83:107-113. doi: 10.1016/j.biopha.2016.06.024. Epub 2016 Jun 23. PMID: 27470557.


12: Pattinson TJ, Gibson CR, Manuel FK, Bishop SL, March WF. The effects of betaxolol hydrochloride ophthalmic solution on intraocular pressures during transient microgravity. Aviat Space Environ Med. 1999 Oct;70(10):1012-7. PMID: 10519481.


13: Allam A, Elsabahy M, El Badry M, Eleraky NE. Betaxolol-loaded niosomes integrated within pH-sensitive in situ forming gel for management of glaucoma. Int J Pharm. 2021 Apr 1;598:120380. doi: 10.1016/j.ijpharm.2021.120380. Epub 2021 Feb 17. PMID: 33609725.


14: Swartz CM. Betaxolol in anxiety disorders. Ann Clin Psychiatry. 1998 Mar;10(1):9-14. doi: 10.1023/a:1026146528290. PMID: 9622045.


15: Li CX, Li H, Zhou YC, Gong ZC, Ling B. Application of topical betaxolol to cure superficial infantile hemangioma: A pilot study. Pediatr Int. 2022 Jan;64(1):e15384. doi: 10.1111/ped.15384. PMID: 36222187.


16: Lešták J, Fůs M, Weissová I, Marešová K. Betaxolol, Brimonidin and Carteolol in the Therapy of Normal-Tension Glaucoma. Cesk Slov Oftalmol. 2020 Spring;76(2):94-97. English. doi: 10.31348/2020/17. PMID: 33126804.


17: Glasser SP, Friedman R, Talibi T, Smith LK, Weir EK. Safety and compatibility of betaxolol hydrochloride combined with diltiazem or nifedipine therapy in stable angina pectoris. Am J Cardiol. 1994 Feb 1;73(4):213-8. doi: 10.1016/0002-9149(94)90221-6. PMID: 8296748.


18: Buckley MM, Goa KL, Clissold SP. Ocular betaxolol. A review of its pharmacological properties, and therapeutic efficacy in glaucoma and ocular hypertension. Drugs. 1990 Jul;40(1):75-90. doi: 10.2165/00003495-199040010-00005. PMID: 2202584.


19: Huang Y, Tao Q, Hou D, Hu S, Tian S, Chen Y, Gui R, Yang L, Wang Y. A novel ion-exchange carrier based upon liposome-encapsulated montmorillonite for ophthalmic delivery of betaxolol hydrochloride. Int J Nanomedicine. 2017 Mar 2;12:1731-1745. doi: 10.2147/IJN.S122747. PMID: 28280338; PMCID: PMC5340245.


20: Sajid Chughtai FR, Zaman M, Khan AH, Amjad MW, Aman W, Khan SM, Ghafoor Raja MA, Nadeem Alvi M, Afridi M, Hanif M. Formulation and evaluation of sustained release ocular inserts of betaxolol hydrochloride using arabinoxylan from Plantago ovata. Pak J Pharm Sci. 2021 May;34(3(Supplementary)):1069-1074. PMID: 34602434.